{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:52:30Z","timestamp":1778111550925,"version":"3.51.4"},"reference-count":18,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25011","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T22:07:48Z","timestamp":1751062068000},"page":"158-161","source":"Crossref","is-referenced-by-count":1,"title":["RB and CHASER as induction therapy for transplant-eligible mantle cell lymphoma"],"prefix":"10.3960","volume":"65","author":[{"given":"Toko","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Yanada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan,"},{"name":"Department of Hematology, Nagoya City University East Medical Center, Aichi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Aichi, Japan,"},{"name":"Department of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitoyo","family":"Kagami","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Taji","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan,"},{"name":"Department of Cell Therapy, Okazaki City Hospital, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waki","family":"Hosoda","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Aichi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Hermine O, Hoster E, Walewski J <i>et al.<\/i> Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016; 388: 565-575.","DOI":"10.1016\/S0140-6736(16)00739-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Yanada M, Yamamoto K. Hematopoietic cell transplantation for mantle cell lymphoma. Int J Hematol. 2022; 115: 301-309.","DOI":"10.1007\/s12185-022-03294-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Ogura M, Yamamoto K, Morishima Y <i>et al.<\/i> R\u2010High\u2010 CHOP \/ CHASER \/ LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer Sci. 2018; 109: 2830-2840.","DOI":"10.1111\/cas.13719"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Oki Y, Ogura M, Kato H <i>et al.<\/i> Phase II study of a salvage regimen using cyclophosphamide, high\u2010dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B\u2010cell non\u2010Hodgkin\u2019s lymphoma. Cancer Sci. 2008; 99: 179-184.","DOI":"10.1111\/j.1349-7006.2007.00662.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Rummel MJ, Niederle N, Maschmeyer G <i>et al.<\/i> Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381: 1203-1210.","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Villa D, Sehn LH, Savage KJ <i>et al.<\/i> Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. Blood Adv. 2020; 4: 3486-3494.","DOI":"10.1182\/bloodadvances.2020002068"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Armand P, Redd R, Bsat J <i>et al.<\/i> A phase 2 study of Rituximab\u2010Bendamustine and Rituximab\u2010Cytarabine for transplant\u2010eligible patients with mantle cell lymphoma. Br J Haematol. 2016; 173: 89-95.","DOI":"10.1111\/bjh.13929"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Merryman RW, Kahl BS, Redd RA <i>et al.<\/i> Rituximab\/Bendamustine and Rituximab\/Cytarabine (RB\/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. Blood. 2018; 132: 145.","DOI":"10.1182\/blood-2018-99-110520"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Le Gouill S, Thieblemont C, Oberic L <i>et al.<\/i> Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med. 2017; 377: 1250-1260.","DOI":"10.1056\/NEJMoa1701769"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Sarkozy C, Thieblemont C, Oberic L <i>et al.<\/i> Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study. J Clin Oncol. 2024; 42: 769-773.","DOI":"10.1200\/JCO.23.01586"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Alaggio R, Amador C, Anagnostopoulos I, <i>et al.<\/i> The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36: 1720-1748.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Cheson BD, Fisher RI, Barrington SF <i>et al.<\/i> Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32: 3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Kato H, Taji H, Ogura M <i>et al.<\/i> Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma. Clin Lymphoma Myeloma. 2009; 9: 443-448.","DOI":"10.3816\/CLM.2009.n.087"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Hiddemann W, Barbui AM, Canales MA <i>et al.<\/i> Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018; 36: 2395-2404.","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Takahashi N, Tsukasaki K, Tanae K <i>et al.<\/i> Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma. J Clin Exp Hematop. 2022; 62: 18-24.","DOI":"10.3960\/jslrt.21018"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Nishikori M, Kitano T, Kobayashi M <i>et al.<\/i> Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine. Int J Hematol. 2015; 102: 53-58.","DOI":"10.1007\/s12185-015-1791-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Dreyling M, Doorduijn J, Gin\u00e9 E <i>et al.<\/i> Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024; 403: 2293-2306.","DOI":"10.1016\/S0140-6736(24)00184-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Wagner-Johnston N, Jegede O, Spurgeon SE <i>et al.<\/i> Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients \u2264 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181. Blood. 2024; 144: 236.","DOI":"10.1182\/blood-2024-194641"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25011\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:45:25Z","timestamp":1751085925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25011\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25011","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25011"}}